230,000 patients,
every year,
running out of
treatment options.
No antibiotic with a new mechanism of action against the most dangerous Gram-negative bacteria has reached the market in decades.
It's time for a different approach.
The Challenge
Every year, 230,000 patients with cystic fibrosis and non-CF bronchiectasis face multidrug-resistant Pseudomonas aeruginosa lung infections.
Beyond these chronic conditions, more than one million patients suffer from acute and hospital-acquired pneumonia each year, contributing to over $2.8 billion in supportive antibiotic treatment costs.
230,000
Patients with CF and non-CF bronchiectasis
1M+
Acute and hospital-acquired pneumonia cases annually
$2.8B+
Estimated supportive antibiotic treatment costs
Conventional antibiotics are losing their effectiveness. Persistent infections lead to progressive lung damage, repeated hospitalizations, poor quality of life, and potentially fatal outcomes.
There are two ways to tackle antibiotic resistance: develop new antibiotics with novel mechanisms of action, or restore the effectiveness of existing ones.
Develop New Antibiotics
Discover new compounds with novel mechanisms of action to overcome bacterial resistance.
However, no meaningful breakthrough is expected in the next decade. The resistance crisis cannot wait.
Restore Antibiotic Activity
Use antibiotic potentiators to help existing antibiotics overcome bacterial resistance and regain their effectiveness.
Great potential for faster development timelines and lower costs. Designed for compatibility with standard of care.
No antibiotic with a new mechanism of action against the most dangerous Gram-negative bacteria has reached the market in decades.
Why wait for new antibiotics when we can make existing ones work again.
That's Why We Developed BismocinTM
Omnicin Therapeutics is developing BismocinTM, an inhaled antibiotic potentiator designed to overcome bacterial resistance and restore the effectiveness of existing antibiotics against Pseudomonas aeruginosa.
At its core is bismuth subcitrate, a well-established compound with decades of clinical use in the oral treatment of Helicobacter pylori infections. Through a proprietary, patent-pending dry powder inhalation formulation, we are opening up an entirely new therapeutic opportunity: restoring antibiotic effectiveness in the treatment of respiratory tract infections.
Not another antibiotic. A smarter way to use the ones we already have.
The Innovation
An established compound. A proprietary formulation. A new therapeutic opportunity.
Transforming bismuth subcitrate from an existing oral treatment into a novel inhaled therapy required more than simply changing the route of administration.
Omnicin has developed a proprietary dry powder formulation, already validated in the Cyclops inhaler, supported by an extensive preclinical data package and a defined pathway towards clinical development.
Established
Efficacy & Safety
50+ years of clinical experience with bismuth compounds, providing a well-established foundation of efficacy and safety for a new therapeutic application.
New Intellectual
Property
Two patent applications filed in 2026.
Two patent-pending innovations: a proprietary dry powder inhalation formulation and a novel bismuth-based composition designed to potentially sustain its therapeutic effectiveness over time.
Accelerated Development
Comprehensive preclinical and CMC packages.
Extensive preclinical and CMC packages, supported by positive BfArM scientific advice. A defined clinical development plan and a potential accelerated US regulatory strategy via the FDA's 505(b)(2) pathway.
Introducing BismocinTM
-
Simple
-
Fast
-
Use at home
A Strategic Partnering Opportunity
One promising technology, multiple paths to commercialization.
Omnicin Therapeutics is seeking a strategic partner to bring BismocinTM towards clinical development and commercialization.
We offer three flexible transaction opportunities: acquisition of the company, outright acquisition of the Bismocin program, or exclusive licensing of the technology.
Company
Acquisition
Acquire 100% of Omnicin Therapeutics, including the BismocinTM program, intellectual property, proprietary formulations, preclinical data and know-how.
Asset
Acquisition
Outright acquisition of the BismocinTM program, including associated intellectual property, preclinical data, CMC documentation and development plans, without acquiring the company.
Exclusive
Licensing
Secure exclusive development and commercialization rights to BismocinTM through a tailored licensing agreement.
Interested in exploring the opportunity?
Contact us to discuss potential transaction structures and request further information under confidentiality.
BismocinTM
More than fighting
infections.